Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dotinurad vs Febuxostat in Chinese Patients With Gout
CTR20212197Phase 3Completed
- Sponsor
- Fuji Yakuhin
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of dotinurad in gout (2 arms), sponsored by Fuji Yakuhin. Primary endpoint: Proportion of subjects with serum uric acid ≤ 6.0 mg/dL at Week 24 (LOCF). Started Sep 2021; status: completed.
02
Drugs
dotinurad
03
Conditions
gout
Beyond the preview
Go deeper on CTR20212197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212197.